CTOs on the Move

Sorrento Therapeutics

www.sorrentotherapeutics.com

 
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento recently announced that NantPharma acquired the rights to Cynviloq™, which completed a successful TRIBECA study. Sorrento is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. In December 2014, Sorrento and NantWorks formed a global joint venture, now called Nantibody, to focus on immunotherapies for cancer. Also in December 2014, Sorrento and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast,® a Natural Killer (NK) cell-line based therapy, entered into ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Sorrento Therapeutics raised $150M on 04/11/2016
Sorrento Therapeutics raised $25M on 10/09/2019

Similar Companies

KaVo Dental Corporation

KaVo Dental Corporation is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TrovaGene

Trovagene is a molecular diagnostics company providing precise, noninvasive urine and blood testing for detecting and monitoring oncogene mutations. By utilizing proprietary technology that analyzes circulating tumor DNA, Trovagene testing offers critical data that may help inform cancer treatment decisions, giving physicians and patients monitoring options beyond biopsy or imaging.

Clinical Research Consultants

Clinical Research Consultants is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioDuro

BioDuro, now a PPD company, is a leading integrated drug discovery outsourcing company that provides high-quality, integrated research and development services to meet the growing needs of the global biotechnology and pharmaceutical industries. Together, PPD and BioDuro have the expertise to perform a broad range of research and development services for pharmaceutical and biotech clients from discovery through Phase IV. Founded in 2005, BioDuro has more than 675 employees, the majority of whom are based in Beijing, where the company operates a state-of-the-art, 110,000-square-foot laboratory. BioDuro provides high-quality medicinal chemistry, discovery biology, pharmacology, synthesis, bioanalytical and drug safety evaluation services. Its discovery biology services range from reagent generation to assay development to screening and biochemistry.

HotSpot Therapeutics

HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways.